The global anticonvulsants market size was USD 18.16 Billion in 2021 and is expected to register a revenue CAGR of 2.3% during the forecast period, according to latest analysis by Emergen Research. Rising high-value investments in the healthcare sector along with increasing Research & Development (R&D) initiative by various major pharmaceutical companies for improvement in anticonvulsant therapy tolerability and drugs are major factors driving market revenue growth. In addition, rising incidences of epilepsy and various neurological disorders along with growing need for pain management caused by migraines are contributing to growth of the anticonvulsants market. Anticonvulsants are medicinal drugs primarily used for treatment of epileptic seizures as well as various psychiatric disorders. High demand for anticonvulsants owing to increasing incidences of bipolar and other disorders consists of recurring aggression, severe temper dysregulation, intellectual impairment, autistic spectrum disorder, and Attention Deficit Hyperactivity Disorder (ADHD). According to National Institute of Mental Health, around 21% of U.S. adults experienced mental illness in 2022, which is around 52.9 million individuals. Moreover, bipolar disorder was estimated for around 7 million individuals, almost 2.8% of the U.S. adults.
The Anticonvulsants Market report presents comprehensive information covering insightful data for businesses and investors for the time period of 2022-2030. The report studies the historical data of the Anticonvulsants market and offers valuable information about the key segments and sub-segments, revenue generation, demand and supply scenario, trends, and other vital aspects. The report offers an accurate forecast estimation of the Anticonvulsants industry based on the recent technological and research advancements. It also offers valuable data to assist the investors in formulating strategic business investment plans and capitalize on the emerging growth prospects in the Anticonvulsants market.
Get a sample of the report @https://www.emergenresearch.com/request-sample/1213
Top competitors of the Anticonvulsants Market profiled in the report include:
GSK Group of Companies, Novartis AG, Pfizer Inc., UCB S.A, Johnson & Johnson Services, Inc., Abbott, Sunovion Pharmaceuticals Inc., Jazz Pharmaceuticals, Inc., Eisai Co., Ltd., and Sanofi.
Some Key Highlights From the Report
The AMPA segment accounted for largest revenue share in 2021. AMPA is utilized in treatment of partial on-set seizures in patients suffering from epilepsy as drugs bind to AMPA receptor present in Central Nervous System (CNS) and block the receptor, which is one of the key factors driving revenue growth of this segment. Two major subtypes of AMPARs, calcium-permeable (CP-AMPARs) and calcium-impermeable (CI-AMPARs) offer different roles in the maintenance of balance in excitation-inhibition of brain.
Better efficacy, fewer side effects, and greater tolerance of second-generation anticonvulsant medications are major factors driving revenue growth of this segment. Moreover, non-requirement of blood level monitoring is increasing demand for second-generation drugs. High demand for anticonvulsant drugs for monotherapy or supplementary therapy is contributing to growth of this segment as well.
The hospital pharmacies segment accounted for a significant revenue share in 2021. Increasing number of hospital pharmacies for neurological disorder, in addition to presence of doctors and medical professionals in both developed as well as emerging countries, are a few key factors driving revenue growth of this segment. Increasing healthcare infrastructure with proper medical supplies and facilities along with high-value funding for development of innovative drugs are contributing to growth of this segment.
The North America market accounted for largest revenue share in 2021. Surging number of various neurological disorders, as well as increasing investments by major pharmaceutical companies for R&D in area of anticonvulsant drug development, are factors driving revenue growth of the market in this region. Furthermore, rising collaborations between governments and pharmaceutical companies and increasing number of approval of new innovative drugs are significantly contributing to growth of the anticonvulsants market.
On 11 March 2022, Lupin which is one of the leading drug firms based in Mumbai, India, was granted USFDA approval to market its anti-epilepsy drug, Vigabatrin for oral solutions (500mg) in the American market. This product is expected to be manufactured in manufacturing facility of Lupin, which is located in Goa.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/anticonvulsants-market
The report further offers a complete value chain analysis along with an analysis of the downstream buyers and upstream raw materials. The study focuses on global trends, regulatory frameworks, and macro- and micro-economic factors. The report also provides an extensive analysis of the segment and sub-segmented expected to dominate the market over the projected period. The report offers a forecast estimation of the market with regards to the analysis of the market segmentation, including product type, end-user industries, application spectrum, and other segments.
Emergen Research has segmented the global anticonvulsants market based on drug type, drug generation, distribution channel, and region:
Drug Type Outlook (Revenue, USD Billion; 2019-2030)
α-Amino-3-Hydroxy-5-Methyl-4-isoxazolepropionic Acid (AMPA)
N-Methyl-D-Aspartate Receptor (NMDAR)
Carbonic Anhydrase Inhibitor
Drug Generation Outlook (Revenue, USD Billion; 2019-2030)
Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)
Regional Analysis of the Anticonvulsants Market:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Request customization of the report @https://www.emergenresearch.com/request-for-customization/1213
The research report on the Anticonvulsants market is formulated through extensive primary and secondary research along with qualitative and quantitative analysis of vital aspects of the market. The insightful data is further validated and verified by the industry professionals. The report strives to offer deeper insights into the overall market scenario of the Anticonvulsants business sphere.
Key Objectives of the Report:
Analysis and estimation of the Anticonvulsants market size and share for the projected period of 2022-2030
Extensive analysis of the key players of the market by SWOT analysis and Porter’s Five Forces analysis to impart a clear understanding of the competitive landscape
Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Anticonvulsants market
Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments
Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities
Click here to Buy Now @https://www.emergenresearch.com/select-license/1213
Thank you for reading our report. Please connect with us to know more about the report or the customization of the report. Our team will ensure the report is best suited to meet your requirements.
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Company Name: Emergen Research
Contact Person: Eric Lee
Email: Send Email
Phone: +1 (604) 757-9756
Address:14671 110 Avenue Surrey, British Columbia, V3R2A9
State: British Columbia